Right at the beginning of the year, the fast-growing pharmaceutical company CHEPLAPHARM Arzneimittel GmbH secures the product rights for CYMEVENE®, KONAKION®, LARIAM® and INHIBACE®/Plus from F.…

Zurich (CH) / Greifswald (DE), December 15, 2017 – In a formal ceremony at the DKSH headquarters in Zurich, DKSH and CHEPLAPHARM Arzneimittel GmbH have signed a strategic partnership for a regional…

According to the motto “We are creating a future with perspectives”, mid-sized companies were honored for their sustainable and successful management by Deloitte and WirtschaftsWoche, together with…

On the occasion of the visit of the German Chancellor Angela Merkel and the Minister of Economics Harry Glawe at CHEPLAPHARM in Greifswald, CEO Sebastian F. Braun announces further investments of 210…

The wholly owned subsidiary of Orexigen Therapeutics, Inc. (OREX), and CHEPLAPHARM Arzneimittel GmbH have executed a distributorship agreement covering Germany, France and Austria for Mysimba®…

The successful company from Greifswald, CHEPLAPHARM Arzneimittel GmbH, continues to grow: 50 new employees have been recruited in the past eight months.

With an investment of approximately 340 million euros, CHEPLAPHARM Arzneimittel GmbH breaks all private sector records in Mecklenburg-Western Pomerania and moves into the big league for medium-sized…

Amount of investment in the mid, double-digit million euro range. CHEPLAPHARM creates eight new jobs with this acquisition.

CHEPLAPHARM acquired the product rights for the prescription medication ALDACTONE® in Italy on 09.11.2015, thus boosting its presence within this market that is very important to CHEPLAPHARM.